Skip to main content
QGEN logo

Qiagen N.V. (QGEN) Stock: Price, Forecast & Analyst Target

Qiagen N.V. (QGEN) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $49.63 (+0.14%), as of the Nov 19, 2026 trading session; market cap $10.3B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 12.41× (cash as of Sep 30, 2026) · expected results Feb 3, 2027

$49.63 +$0.07 (+0.14%) Market Cap $10.3B

Qiagen N.V. · QGEN · NYSE · Healthcare · Medical Diagnostics & Research

Research dated 2026-09-13: QIAGEN sells the tools that move biological material from collection and purification through molecular testing and interpretation, with consumables supplying most of its revenue. The case rests on whether its installed workflows can generate durable consumables demand while restrained sales growth, sizable debt and a shrinking cash balance leave less room for disappointment.

Price as of Nov 19, 2026

Key Statistics

83 of 100

MoonshotScore v2 · Qiagen (QGEN)

Exceptional
Business Quality Elite (85)
Financial Safety Sound (72)
Valuation Full (55)
Growth Durability Flat (58)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $533M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 4.04 · Piotroski F 9

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for QGEN (52 recorded, newest six shown)
RecordedScoreBand
88Exceptional
88Exceptional
88Exceptional
88Exceptional
83Exceptional
83Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$49.63
Change on the day+0.14%
52-week range$32.53–$57.82
Market capitalisation$10.3B—
Price / earnings (trailing)26.75
Shares traded on the day2.74M
Beta (volatility vs the S&P 500)0.56
Dividends per share (last 12 months)$2.64
Dividend yield (last 12 months)5.31%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $33, high $56, latest $50. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $56 $33 high $56 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $511May 6, 2026 · Earnings results · reported below the recorded estimate · close $332Aug 5, 2026 · Earnings results · reported above the recorded estimate · close $423Aug 6, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $424Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $505 Oct 17, 2025 Nov 19, 2026 · $50 $48Oct 17, 2025$47Oct 31, 2025$44Nov 14, 2025$48Nov 28, 2025$45Dec 12, 2025$48Dec 26, 2025$48Jan 9, 2026$56Jan 23, 2026$51Feb 6, 2026$49Feb 20, 2026$45Mar 6, 2026$40Mar 20, 2026$41Apr 2, 2026$41Apr 17, 2026$34May 1, 2026$33May 15, 2026$37May 29, 2026$37Jun 12, 2026$39Jun 26, 2026$42Jul 10, 2026$41Jul 24, 2026$42Aug 7, 2026$44Aug 21, 2026$43Sep 4, 2026$43Sep 18, 2026$45Oct 2, 2026$46Oct 16, 2026$50Oct 30, 2026$50Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER.

    Roland Sackers · Statement from

  • For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER.

    Roland Sackers · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Qiagen (QGEN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Qiagen (QGEN), and what does it report?

Short answer · as of

QIAGEN is not chiefly a laboratory-instrument vendor.

It supplies purification kits, assay consumables, amplification products, sequencing preparation, diagnostic tests, instruments, bioinformatics and software to molecular-diagnostics and life-science customers; instruments place workflows, while recurring kit and assay use drives the larger revenue pool.

Reported revenue therefore blends demand from research laboratories and clinical testing with product categories spanning sample preparation, diagnostic solutions, genomics and nucleic-acid amplification. The consumables-heavy mix matters because testing and experiment volume can influence sales after an instrument has already been installed.

2 · Latest results

What do the latest results show for Qiagen (QGEN)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $533M.

The latest reported period brought a rebound from the preceding period: revenue, gross profit, operating profit, net income and cash generated from operations all increased. Revenue also came in above the prevailing estimate, reversing the modest shortfall recorded in the prior report.

Across the broader annual series, sales have recovered from their trough but remain below the earlier peak, while net income has been far less stable than revenue. Management has reaffirmed modest constant-currency sales growth, framing the near-term path as gradual expansion rather than a sharp acceleration.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$547.87M Sep 30, 2026
Latest quarter · R&D
$53.95M Sep 30, 2026
Latest quarter · SG&A
$146.13M Sep 30, 2026
Latest quarter · FMP standardized operating result
$151.64M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$547.87M$53.95M$146.13M$151.64M
Jun 30, 2026$535.04M$50.43M$146.77M$132.40M
Mar 31, 2026$492.32M$48.26M$142.39M$116.63M
Dec 31, 2025$540.42M$47.23M$153.88M$153.90M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$548.00M Nov 4, 2026
Latest report · revenue estimate
$538.61M Nov 4, 2026
Latest report · revenue vs estimate
Above estimate Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026$548.00M$538.61M$0.6500$0.6270
Aug 5, 2026$535.04M$527.50M$0.6200$0.5980
May 6, 2026$492.32M$496.15M$0.5400$0.5420
Feb 4, 2026$540.42M$528.42M$0.6200$0.6100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$533M$130M$0.60 (diluted)
Q4 FY2025$540M$108M$0.52 (diluted)
Q1 FY2026$492M$68M$0.33 (diluted)
Q2 FY2026$535M$103M$0.50 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Qiagen (QGEN)?

Short answer · as of

Cash and short-term investments were $830.13M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $145.63M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

QIAGEN converts operations into cash consistently, and recent operating cash flow has remained comfortably above capital spending. Profitability is also substantial across gross, operating and net measures, while the quality and distress screens do not signal immediate financial strain.

The counterweight is leverage. Debt exceeds cash and investments, leaving the company in a net-debt position, and cash has declined materially across the reported window despite positive operating cash generation. The distribution pattern has also varied sharply, so recent dividend yield should not be treated as a dependable run rate without examining the underlying payments.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$145.63M Sep 30, 2026
Previous quarter · operating cash flow
$200.69M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$145.63M−$40.03M
Jun 30, 2026$200.69M−$42.93M
Mar 31, 2026$100.63M−$46.88M
Dec 31, 2025$188.13M−$70.91M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Qiagen (QGEN)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

QIAGEN now needs to show that the latest sequential rebound can persist without sacrificing margin or cash conversion. Watch revenue against management’s modest constant-currency outlook, gross and operating profit alongside research and selling costs, and operating cash flow after capital spending.

The balance sheet deserves equal attention: stabilization in cash and short-term investments would make the leverage position less restrictive, while another material decline would raise questions about uses of cash beyond ordinary investment. Consensus expects continuing revenue and earnings growth over the forecast horizon, making execution against that gradual path more informative than any isolated estimate beat.

What management is planning

Management's statements are quoted under Upcoming events

What the records here don't tell us

  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Qiagen compare with its peers?

Short answer

Qiagen's score ranks tied for 2nd of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

QIAGEN spans more of the molecular workflow than a focused assay maker or instrument supplier: sample stabilization and purification feed amplification, sequencing preparation, diagnostic assays and software interpretation. That breadth can deepen customer workflow exposure, but it also ties performance to a varied mix of research activity, clinical testing and consumable pull-through.

Its revenue base is dominated by consumables and related products rather than instruments alone. Investors are therefore evaluating a recurring-use model with broad workflow coverage, while current valuation measures and consensus forecasts already assume profitable, continued expansion rather than a distressed recovery.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Named competitor$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Qiagen (QGEN) — this page$49.63$10.3B83
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Named competitor$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
Revvity, Inc. (RVTY) Named competitor$151.59 Nov 19, 2026$16.9B71 5-pillar Nov 18, 2026
BioMarin Pharmaceutical Inc. (BMRN) Named competitor$61.43 Nov 18, 2026$11.9B58 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$38.60 – $52.00
Consensus target
$45.71
Median target
$46.25

Consensus record · Captured .

Measured against a quoted price of $49.63 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
69.6% Period end Sep 30, 2026
Previous quarter · ownership
70.7% Prior to period end Sep 30, 2026
Reporting holders
388 Period end Sep 30, 2026
Previous quarter · holders
366 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Price T Rowe Associates INC /Md/16,438,820
Wellington Management Group Llp11,636,224
Principal Financial Group INC8,395,501
Vanguard Capital Management LLC6,256,165
Blackrock, INC.5,807,458

Tracked investors

Which of the 16 named investors we follow held QGEN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported QGEN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Qiagen (QGEN)?

Read these with our analysis →

What Investors Ask About Qiagen (QGEN) — Healthcare

The last 3 questions are answered from this page's own dated data, not from the research.

Why are QIAGEN Sample Technologies important to the business?

Sample Technologies place QIAGEN at the start of molecular workflows through stabilization, purification and preparation of nucleic acids. Repeated processing of biological samples supports consumables demand before downstream amplification, sequencing or diagnostic interpretation begins.

Does QIAGEN depend mainly on selling laboratory instruments?

Consumables and related products form the dominant reported revenue category. Instruments support adoption of QIAGEN workflows, but recurring kits, assays and other consumables carry greater economic weight.

What makes QIAGEN’s QuantiFERON-style immune response testing different from its research products?

Immune-response assays serve clinical testing needs such as tuberculosis and post-transplant monitoring, while research products support gene expression, genotyping and related laboratory work. QIAGEN participates in clinical and research workflows rather than relying on a narrow testing market.

Why does QIAGEN’s cash position need watching despite strong operating cash flow?

Operations have generated cash above capital spending, yet cash and short-term investments have fallen materially across the reported window and remain below total debt. Continued cash conversion must therefore be assessed alongside leverage, distributions and other uses of liquidity.

What is the QGEN stock price today?

The last price recorded for Qiagen N.V. (QGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the QGEN price target?

The analyst consensus price target for Qiagen N.V. (QGEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Does QGEN pay a dividend?

Yes. The dividend yield of Qiagen N.V. (QGEN) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 1. What is Qiagen (QGEN), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • 2. What do the latest results show for Qiagen (QGEN)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Qiagen (QGEN)?: Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Recent dividends paid; Dividends per share, last 12 months (split-adjusted); Dividend yield, last 12 months
  • 4. What should you watch next at Qiagen (QGEN)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 5. How does Qiagen compare with its peers?: Business description; Revenue by segment; Trailing twelve-month ratio set; Distress and quality screens; Analyst revenue and earnings estimates (average)
  • FAQ: Why are QIAGEN Sample Technologies important to the business?: Business description; Revenue by segment
  • FAQ: Does QIAGEN depend mainly on selling laboratory instruments?: Business description; Revenue by segment
  • FAQ: What makes QIAGEN’s QuantiFERON-style immune response testing different from its research products?: Business description; Revenue by segment
  • FAQ: Why does QIAGEN’s cash position need watching despite strong operating cash flow?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Recent dividends paid
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.